Skip to search formSkip to main contentSkip to account menu

M 16209

Known as: 2,4-Imidazolidinedione, 1-((3-bromo-2-benzofuranyl)sulfonyl)-, M-16209, M16209 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

BenzofuransHydantoins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1997
1997
Antihyperglycemic mechanism of M16209, an antidiabetic agent, in 3T3-L1 adipocytes.
1996
1996
Amelioration of insulin resistance in genetically obese rodents by M16209, a new antidiabetic agent.
1996
1996
Effects of M16209, a new antihyperglycemic agent, on insulin sensitivity in vivo: euglycemic clamp studies in rats.
1996
1996
Acceleration of glycolysis in erythrocytes by the antidiabetic agent M16209.
The effects of M16209 (1-(3-bromobenzofuran-2-ylsulfonyl)hydantoin), an antidiabetic agent and aldose reductase inhibitor, on… 
1995
1995
Effects of M16209 on insulin secretion in isolated, perfused pancreases of normal and diabetic rats.
1995
1995
Antihyperglycemic effects of M16209, a novel aldose reductase inhibitor, in normal and diabetic rats.
1991
1991
Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats.
1990
1990
Effects of novel hydantoin derivatives with aldose reductase inhibiting activity on galactose-induced cataract in rats.
Effects of novel aldose reductase inhibitors, M16209 (1-(3-bromobenzo[b]furan-2-ylsulfonyl)hydantoin) and M16287 (1-(3… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)